BridgeBio Oncology Therapeutics (BBOT) Operating Expenses (2024 - 2026)

BridgeBio Oncology Therapeutics has reported Operating Expenses for 3 years, with the latest figure at $46.2 million in Q1 2026.

• Quarterly Operating Expenses rose 99.59% year-over-year to $46.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $139.9 million (up 115.77% YoY) and the FY2025 annual result came in at $145.8 million, up 80.33% from the prior year.
• Operating Expenses advanced to $46.2 million in Q1 2026 per BBOT's latest filing, from $43.4 million in the prior quarter.
• Over five years, Operating Expenses peaked at $49.2 million in Q3 2025 and troughed at $66701.0 in Q1 2024.
• A 3-year average of $22.8 million and a median of $21.9 million in 2024 frame the typical range for Operating Expenses.
• The widest YoY moves for Operating Expenses: up 34587.64% in 2025, down 98.4% in 2025.
• Over 3 years, Operating Expenses stood at $21.9 million in 2024, then surged by 98.4% to $43.4 million in 2025, then advanced by 6.38% to $46.2 million in 2026.
• According to Business Quant data, Operating Expenses over the past three periods registered $46.2 million, $43.4 million, and $49.2 million for Q1 2026, Q4 2025, and Q3 2025 respectively.